Rani Therapeutics Holdings, Inc.

2024 was an eventful year for the South Korean biopharma industry with the emergence of several key themes that look set to carry over into the new year. The sector is facing a new growth chapter fuel

Glucagon-like peptide-2 (GLP-2) is known to have strong efficacy in reducing the low-grade systemic inflammation related to various cardiovascular, renal, liver and neurodegenerative disorders. While

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. ProGen Partners With Rani To Devel

Rani Therapeutics has shared positive topline data from a Phase I trial of its orally administered biosimilar to Johnson & Johnson’s (J&J’s) Stelara (ustekinumab) known as RT-111 after undertaking st